Intensity Therapeutics (INTS) Income from Continuing Operations (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Income from Continuing Operations came in at 2545000.0 in Q1 2026, up 25.06% YoY from 2035041.21 in Q1 2025, and up 17.1% on a QoQ basis from 3070000.0 in Q4 2025.
Intensity Therapeutics (INTS) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Income from Continuing Operations data on file, last reported at 2545000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 25.06% year-over-year to 2545000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11147000.0 (up 26.17% YoY) and the FY2025 annual result came in at 11860000.0, up 63.5% from the prior year.
- Income from Continuing Operations advanced to 2545000.0 in Q1 2026, from 3070000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1337000.0 in Q1 2023 to a low of 4990000.0 in Q2 2024.
- A 5-year average of 2796457.81 and a median of 2766000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 244.5% — and 2025, when it jumped 45.35%.
- Tracing INTS's Income from Continuing Operations over 5 years: stood at 1510798.0 in 2022, then tumbled by 110.22% to 3176000.0 in 2023, then grew by 0.06% to 3174000.0 in 2024, then advanced by 3.28% to 3070000.0 in 2025, then climbed by 17.1% to 2545000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2545000.0 (Q1 2026), 3070000.0 (Q4 2025), and 2805000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | -3.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.11 Mn |
| Mar 31, 2026 | -2.55 Mn |
| Dec 31, 2025 | -3.07 Mn |
| Sep 30, 2025 | -2.81 Mn |
| Jun 30, 2025 | -2.73 Mn |
| Mar 31, 2025 | -3.40 Mn |
| Dec 31, 2024 | -3.17 Mn |
| Sep 30, 2024 | -3.54 Mn |
| Jun 30, 2024 | -4.99 Mn |
| Mar 31, 2024 | -4.61 Mn |
| Dec 31, 2023 | -3.18 Mn |
| Sep 30, 2023 | -2.43 Mn |
| Jun 30, 2023 | -1.71 Mn |
| Mar 31, 2023 | -1.34 Mn |
| Dec 31, 2022 | -1.51 Mn |
| Sep 30, 2022 | -1.78 Mn |
| Jun 30, 2022 | -1.94 Mn |